-
公开(公告)号：US20240000939A1
公开(公告)日：2024-01-04
申请号：US18368647
申请日：2023-09-15
发明人： Jaap Jan Boelens , Kevin J. Curran
IPC分类号： A61K39/00 , C12N5/0783 , A61K31/7076 , A61P35/02
CPC分类号： A61K39/464412 , C12N5/0636 , A61K39/4622 , A61K39/4631 , A61K39/464411 , A61K39/4611 , A61K31/7076 , A61P35/02 , A61K2239/11 , A61K2239/22 , A61K2239/48
摘要： The present disclosure relates to treating a subject comprising administering to the subject a therapy (e.g., a cell therapy, e.g., an adoptive cell therapy, e.g., a CAR-T cell therapy), wherein, prior to the administration, the subject has been preconditioned with a personalized amount of a chemotherapeutic agent. The personalized amount provides an optimal exposure to the chemotherapeutic agent.
-
公开(公告)号：US20240101668A1
公开(公告)日：2024-03-28
申请号：US18447138
申请日：2023-08-09
申请人： WUGEN, Inc.
发明人： Ayman KABAKIBI , Alexander S. HAMIL
CPC分类号： C07K16/2803 , A61K39/4611 , A61K39/4631 , A61P37/04 , C07K16/2851 , C07K16/2863 , C12N15/86 , A61K2239/11 , A61K2239/21 , C07K2317/24 , C07K2317/565 , C07K2317/622 , C12N2740/15043
摘要： Disclosed herein are polypeptides, such as monoclonal antibodies (mAbs) and functional fragments thereof, synthetic antigen-binding proteins such as single-chain variable fragments (scFvs), and chimeric antigen receptors (CARs), that can specifically recognize tumor-associated antigens (TAAs) on cancer cells, for example those that express CD33, FLT3, and CLL-1, useful in the treatment of diseases such as cancer.
-
公开(公告)号：US20240226295A9
公开(公告)日：2024-07-11
申请号：US18546384
申请日：2022-02-15
发明人： Chantal KUHN , Gary SHAPIRO
CPC分类号： A61K39/4631 , A61K35/17 , A61P35/00 , A61P37/02 , C12N5/0636 , C12N15/63 , A61K2239/11 , A61K2239/21 , A61K2239/22 , C12N2510/00
摘要： Methods of using polypeptides to modulate transforming growth factor-β (TGFβ) signaling (e.g., TGFβ receptors, antibodies or antigen-binding fragments thereof that specifically bind TGFβ or a TGFβ receptor) are provided. Compositions comprising the antibodies or fragments thereof and methods of using the same for treatment of diseases involving TGFβ activity are provided. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions comprising these antigen binding agents and fragments thereof are also disclosed. The invention also provides therapeutic methods for utilizing the TGFβ signaling modulators are provided herein.
-
公开(公告)号：US20240131158A1
公开(公告)日：2024-04-25
申请号：US18546384
申请日：2022-02-15
发明人： Chantal KUHN , Gary SHAPIRO
CPC分类号： A61K39/4631 , A61K35/17 , A61P35/00 , A61P37/02 , C12N5/0636 , C12N15/63 , A61K2239/11 , A61K2239/21 , A61K2239/22 , C12N2510/00
摘要： Methods of using polypeptides to modulate transforming growth factor-β (TGFβ) signaling (e.g., TGFβ receptors, antibodies or antigen-binding fragments thereof that specifically bind TGFβ or a TGFβ receptor) are provided. Compositions comprising the antibodies or fragments thereof and methods of using the same for treatment of diseases involving TGFβ activity are provided. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions comprising these antigen binding agents and fragments thereof are also disclosed. The invention also provides therapeutic methods for utilizing the TGFβ signaling modulators are provided herein.
-
公开(公告)号：US20240000836A1
公开(公告)日：2024-01-04
申请号：US18039420
申请日：2021-12-03
发明人： Jordan Mark SCHECTER , Xiaohu FAN
CPC分类号： A61K35/17 , A61K39/4611 , A61K39/4631 , A61K39/464417 , A61P35/00 , A61K2039/505 , A61K2239/11 , A61K2239/21 , A61K2239/22 , A61K2239/31 , A61K2239/38
摘要： Provided herein is a method of treating a subject who has multiple myeloma. A single infusion of chimeric antigen receptor (CAR)-T cells comprising an anti-BCMA CAR comprising a polypeptide is administered to the subject. In certain embodiments, the dose of CAR-T cells administered to the subject is from 1.0×105 to 5.0×106 of CAR-T cells per kilogram of the subject's mass. The method of treatment is effective in obtaining and maintaining minimal residual disease negativity status, as well as other beneficial clinical outcomes related to efficacy and safety.
-
公开(公告)号：US20230338534A1
公开(公告)日：2023-10-26
申请号：US17915737
申请日：2021-04-08
申请人： AUTOLUS LIMITED
发明人： Martin Pulé
IPC分类号： A61K39/00
CPC分类号： A61K39/4637 , A61K39/4631 , A61K39/46433 , A61K39/4644 , A61K39/46449 , A61K39/4611 , A61K39/464412 , A61K39/464411 , A61K39/4622 , A61K39/464463 , A61K2239/17 , A61K2239/11 , A61K2239/26 , A61K2239/57 , A61K2239/46
摘要： The present invention provides a method for treating a disease in a subject, which comprises the step of administering to the subject a plurality of cells which express: (a) a chimeric antigen receptor (CAR); and (b) a mutant version of calcineurin A and/or calcineurin B which is resistant to the calcineurin inhibitor. The subject may be receiving or have received treatment with a calcineurin inhibitor. The CAR-expressing cells may be administered prior to, following, simultaneously with or in combination with a calcineurin inhibitor.
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.014 秒)
